SMC Ventures

SMC is a specialized biotechnology company and contract research organization (CRO) focused on the development of therapies for fibrosis and inflammation-related diseases, particularly metabolic dysfunction-associated steatohepatitis (MASH/NASH). The company is globally recognized for its proprietary STAM mouse model, which is widely considered the gold standard for studying the progression of NASH into liver fibrosis and hepatocellular carcinoma. Beyond its CRO services, SMC engages in drug discovery and development through its internal research programs and strategic partnerships. The company provides comprehensive preclinical pharmacology services, including efficacy testing, histological analysis, and biomarker discovery for global pharmaceutical and biotech clients.